Radiopharm Seeks Shareholder Approval for Expanded A$18.5M Capital Raise and Director SPP Participation
RADX is trading near its 52-week low of $2.62 (3.1% above the low).
Summary
Radiopharm Theranostics has called an EGM for 11 September 2026 to approve the remaining components of its A$18.5 million capital raise, including second tranche placement shares, attaching options, an expanded SPP, shortfall options, ADR warrants, agent warrants, and director participation in the SPP.
Key Events · Financing and Capital Events · RADX
-
EGM Called for 11 September 2026
Radiopharm Theranostics will hold an Extraordinary General Meeting virtually on 11 September 2026 to vote on resolutions related to its A$18.5 million capital raise.
-
Second Tranche Placement Approval Sought
Resolution 2 seeks approval to issue up to 40,000,000 Placement Shares at A$0.015 per share, expected to be allotted on or about 17 September 2026.
-
Attaching Options and SPP Expansion
Resolutions 3 and 4 seek approval for 448,839,531 Placement Attaching Options and up to 666,666,667 SPP Shares with 666,666,667 SPP Attaching Options, with the SPP cap increased to A$10 million.
-
Shortfall and Warrant Approvals
Resolutions 5, 6, and 7 seek approval for 200,000,000 Shortfall Options to Trading Capital Management, 1,281,646 ADR Warrants at US$3.79, and 64,082 Agent Warrants to H.C. Wainwright at US$3.95.
Analysis · RADX · Life Sciences
Radiopharm Theranostics has called an Extraordinary General Meeting for 11 September 2026 to ratify and approve the remaining components of its A$18.5 million capital raise announced on 24 July 2026. The notice seeks approval for the second tranche placement of 40 million shares, 448.8 million attaching options, an expanded SPP of up to A$10 million with 666.7 million shares and options, 200 million shortfall options, 1.28 million ADR warrants, and 64,082 agent warrants. It also seeks approval for directors to participate in the SPP for up to 7.33 million shares and options. The company is trading near its 52-week low of $2.62, and the capital raise is critical given its Q2 2026 cash balance of A$4.1 million and only 0.28 quarters of runway. The EGM is a necessary step to complete the financing and replenish placement capacity under ASX Listing Rule 7.1.
At the time of this filing, RADX was trading at $2.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $36.7M. The 52-week trading range was $2.62 to $16.25. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.